CMS Finalizes Rule Prohibiting Federal Medicaid and CHIP Funding for Sex-Rejecting Procedures for Minors

The Centers for Medicare & Medicaid Services (CMS), an agency within the Department of Health and Human Services (HHS), has finalized a rule that significantly alters the landscape of federal funding for healthcare services related to gender identity for minors. Effective October 13, 2026, this new regulation prohibits federal matching funds under both Medicaid and the Children's Health Insurance Program (CHIP) for what the agency defines as "sex-rejecting procedures" furnished to individuals under specific age thresholds.

The New Regulatory Framework

Under the finalized rule, State Medicaid plans must now include a provision ensuring that the State agency will not make payments for "sex-rejecting procedures" for children under the age of 18. Similarly, separate State CHIP plans must prohibit payment for such procedures for children under 19. This means that federal dollars will no longer contribute to the cost of these specific medical interventions for these age groups through these critical public health programs.

Recognizing the impact on current beneficiaries, the rule includes a transitional provision. For Medicaid and CHIP beneficiaries who are actively receiving cross-sex hormone therapy at the time the rule becomes effective, State agencies may continue to claim Federal Financial Participation (FFP) for those hormone therapy medications for a period of up to six months from the rule's effective date. This allows for a limited period of adjustment for existing treatment plans.

It is important to note that this federal prohibition does not entirely block access to these procedures. States retain the option to provide coverage for "sex-rejecting procedures" using only State-only funds, meaning without any federal match. Furthermore, the rule does not preclude the use of other non-federal funding sources, including private insurance, for these services.

Statutory Authority and Policy Directives

The CMS action is rooted in several provisions of the Social Security Act. For Medicaid, the agency cites sections 1902(a)(19) and 1902(a)(30)(A). Section 1902(a)(19) requires safeguards to ensure care and services are provided in a manner consistent with the best interests of recipients. Section 1902(a)(30)(A) mandates methods and procedures to assure that payments are consistent with quality of care. For CHIP, the rule invokes section 2103, which guides the provision of child health assistance, and section 2101(a), emphasizing effective and efficient administration and coordination. Additionally, section 1102 grants the Secretary of HHS authority to make necessary rules for the efficient administration of functions under the Act.

This final rule also directly addresses directives issued by President Trump. Specifically, it responds to Section 5(a) of Executive Order (E.O.) 14187, titled "Protecting Children from Chemical and Surgical Mutilation," issued on January 28, 2025. This order directed the Secretary to take actions consistent with applicable law to end what the order termed the "chemical and surgical mutilation of children," including regulatory actions for specific programs like Medicaid.

Navigating Judicial Scrutiny

The implementation of policies related to gender-affirming care has faced significant legal challenges. CMS acknowledges that preliminary injunctions have been issued by federal district courts against certain sections of presidential executive orders related to "gender-affirming care."

The U.S. District Court for the Western District of Washington, in Washington v. Trump (2025), enjoined defendant agencies from enforcing sections of E.O. 14187 and E.O. 14168 (Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government) that conditioned or withheld federal funding based on the provision of "gender-affirming care" within the plaintiff states.

Similarly, the U.S. District Court for the District of Maryland, in PFLAG, Inc. v. Trump (2025), issued a preliminary injunction against conditioning, withholding, or terminating federal funding under section 3(g) of E.O. 14168 and section 4 of E.O. 14187, where it concerned "gender-affirming care" for patients under 19.

CMS asserts that this final rule does not conflict with these preliminary injunctions. The agency states that its rule is based on independent legal authority derived from the Social Security Act and specifically implements section 5(a) of President Trump's E.O. 14187, rather than the enjoined sections of the executive orders.

Implications for Healthcare and Policy

The implementation of this final rule will have substantial effects across various sectors. For states, it necessitates adjustments to their Medicaid and CHIP program designs and funding mechanisms, particularly if they wish to continue covering "sex-rejecting procedures" for minors using state funds. Healthcare providers who serve minor populations seeking these services will need to navigate altered reimbursement structures and potentially new guidelines. For families and young beneficiaries, access to federally funded care for these procedures will cease, potentially creating disparities based on state-level funding decisions or private insurance coverage.

This policy also underscores the ongoing and deeply contentious debate at both federal and state levels regarding the appropriate age for minors to access certain medical interventions related to gender identity. The rule represents a federal stance that these specific procedures for minors are not consistent with the "best interests of the recipients" or "quality of care" as interpreted by CMS under its statutory authority and presidential direction.